SERA PROGNOSTICS, INC. SERA
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
2/9
Piotroski F — financial health
-8.32
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $81,000 | -$31.9M | — | -$26.3M | $75.4M |
| 2024 | $77,000 | -$32.9M | — | -$14.2M | $47.8M |
| 2023 | $306,000 | -$36.2M | — | -$27.3M | $70.2M |
| 2022 | $268,000 | -$44.2M | — | -$35.4M | $98.9M |
| 2021 | $82,000 | -$35.0M | — | -$32.9M | $138.6M |
| 2020 | $25,000 | -$19.8M | — | -$17.0M | -$125.6M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.32 (distress)
- Working capital / assets 0.163
- Retained earnings / assets -3.058
- EBIT / assets -0.358
- Equity / liabilities 2.843
Source: SEC EDGAR filings · CIK 0001534969 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.